top of page
News
Press Releases
Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in Mature T-Cell Lymphoma Published in European Journal of Haematology
Dublin, Ireland, April 6 2025 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...
Apr 6
Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in PTCL Presented at the Inaugural West German Lymphoma Symposium
Dublin, Ireland, June 4 2024 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...
Jun 4, 2024
Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics
Dublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...
Aug 21, 2023
Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022
Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...
Dec 5, 2022
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence
ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...
May 30, 2022
Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease
Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...
May 27, 2022
bottom of page